Duloxetine. Depression and diabetic neuropathy: Too many adverse effects

Prescrire International

Volumn 15, Issue 85, 2006, Pages 168-172

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DULOXETINE; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; THIOPHENE DERIVATIVE;

ANALGESIC ACTIVITY; ANOREXIA; ARTICLE; BLURRED VISION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; EUROPEAN UNION; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; LIVER DISEASE; MENTAL DISEASE; MYDRIASIS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PREGNANCY; PROSTATE HYPERTROPHY; QT PROLONGATION; RISK ASSESSMENT; SHORT COURSE THERAPY; STRESS INCONTINENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SWEAT GLAND DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; WITHDRAWAL SYNDROME; XEROSTOMIA; ADULT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; DEPRESSION; DIABETIC NEUROPATHIES; EUROPEAN UNION; FEMALE; FIBROMYALGIA; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 33749323280     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. "Depression". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press London 2005: 279-280.
2. Prescrire Editorial Staff "Neuropathic pain in diabetic patients" Prescrire Int 2004; 13 (71): 111.
3. o. Scientific discussion" 17 December 2004: 35 pages.
4. Prescrire Editorial Staff "Duloxetine" Prescrire Int 2005; 14 (80): 218-220.
5. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-427 Medical review no 3" 19 August 2002: 93 pages.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-427 Statistical review" 4 September 2002: 23 pages.
7. Goldstein DJ et al. "Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial" J Clin Psychiatry 2002; 63: 225-231.
8. Eli Lilly "Synopsis ID no 3327. Clinical study synopsis: study F1J-MC-HMAQ Study Group A" 16 November 2004: 31 pages.
9. Eli Lilly "Summary ID no 3327. Clinical study summary: study F1J-MC-HMAQ Study Group B" 16 November 2004: 26 pages.
10. Detke MJ et al. "Duloxetine, 60 mg once daily, for major depressive disorder; a randomized double-blind placebo-controlled trial" J Clin Psychiatry 2002; 63 (4): 308-315 + 64 (1): 96-97.
11. Eli Lilly "Summary ID no 4689. Clinical study summary: study F1J-MC-HMBH Study Group A" 15 November 2004: 20 pages.
12. Detke MJ et al. "Duloxetine, 60 mg once daily dosing versus placebo in the acute treatment of major depression" J Psychiatr Res 2002; 36: 383-390.
13. Eli Lilly "Summary ID no 4689. Clinical study summary: study F1J-MC-HMBH Study Group B" 23 November 2004: 21 pages.
14. Eli Lilly "Summary ID no 4091. Clinical study summary: study F1J-MC-HMAT Study Group A" 16 November 2004: 24 pages.
15. Eli Lilly "Summary ID no 4091. Clinical study summary: study F1J-MC-HMAT Study Group B" 16 November 2004: 23 pages.
16. Goldstein DJ et al. "Duloxetine in the treatment of depression" J Clin Psychopharmacol 2004; 24: 389-399.
17. Detke MJ et al. "Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and paroxetine-controlled trial" Eur Neuropsychopharmacol 2004; 14 (6): 457-470.
18. o. Scientific discussion" 4 July 2005: 10 pages.
19. Goldstein DJ et al. "Duloxetine vs placebo in patients with painful diabetic neuropathy" Pain 2005; 116 (1-2): 109-118.
20. Gilliland BC "Fibromylgia, arthritis associated with systemic disease, and other arthritis". In: Kasper DC et al. "Harrison's principles of internal medicine" 16th ed., McGraw-Hill, New York 2005: 2055-2064.
21. Arnold LM et al. "A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder" Arthritis Rheum 2004; 50 (9): 2974-2984.
22. Arnold LM et al. "A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder" Pain 2005; 119: 5-15.
23. Brannan SK et al. "Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder" J Psychiatr Res 2005; 39: 43-53.
24. Goldstein DJ et al. "Effects of duloxetine on painful physical symptoms associated with depression" Psychosomatics 2004; 45 (1): 17-28.
25. Fava M et al. "The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?" J Clin Psychiatry 2004; 65: 521-530.
26. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Review and evaluation of clinical data. Safety team leader review of selected safety issues in the response to approval letter - NDA 21-427" 22 September 2003: 22 pages.
27. o (duloxetine hydrochloride) - Hepatic effects - Dear Health Professional" 5 October 2005: 2 pages.
28. Skinner MH et al. "Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers" Clin Pharmacol Ther 2003; 73: 170-177.